Discounted Cash Flow (DCF) Analysis Unlevered

Krystal Biotech, Inc. (KRYS)

$115.58

+0.23 (+0.20%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 115.58 | undervalue

Operating Data

Year
A/P
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 1.03---------
Revenue (%)
EBITDA -11.77---------
EBITDA (%)
EBIT -11.92---------
EBIT (%)
Depreciation 0.14---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Total Cash 111.76---------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 0.89---------
Accounts Payable (%)
Capital Expenditure -2.23---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 115.58
Beta 0.827
Diluted Shares Outstanding 25.49
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 58.45%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.532
Total Debt 8.93
Total Equity 2,946.33
Total Capital 2,955.27
Debt Weighting 0.30
Equity Weighting 99.70
Wacc

Build Up Free Cash

Year
A/P
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 1.03---------
EBITDA -11.77---------
EBIT -11.92---------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT -11.92---------
Depreciation 0.14---------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -2.23-6.40-14.84-68.34-52.98-----
UFCF -14.01---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 8.68
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -152.97
Equity Value -
Shares Outstanding 25.49
Equity Value Per Share -